Can Patch Testing Still Help During Dupilumab Treatment? Reading Conflicting Results
A persistent patch of dermatitis during dupilumab treatment can raise two questions: could contact allergy still be contributing, and can testing detect it reliably? Research supports the potential usefulness of patch testing, but results about reproducibility have differed. A positive or negative result needs specialist interpretation rather than a blanket rule about the medicine.
A prospective study found clinically relevant results
A multicenter prospective study published in 2024 examined 76 dupilumab-treated patients. Thirty-six had at least one positive patch reaction, and 23 had at least one positive result judged clinically relevant. Five experienced eczema improvement after allergen avoidance. These were selected patients being investigated, not a population sample showing how commonly every dupilumab user has contact allergy.
In 36 participants tested before and during treatment, investigators compared 1,230 paired allergen results: 1,022 were unchanged, 34 became positive, 44 were lost and 130 were uninterpretable. Overall agreement is not the same as sensitivity for a previously positive allergen, particularly when many comparisons are negative.
Why another study looked less reassuring
A 2021 retrospective evaluation included 20 patients with 56 previously positive reactions. Only 16 reactions, or 29%, remained positive during dupilumab treatment. The median interval between testing rounds was 5.5 years. Stronger initial reactions were more reproducible than weaker ones. The authors raised possible treatment-related suppression and false-negative results.
The reports differ in selection, testing intervals and what is counted. A long interval can introduce influences other than the drug. Neither small study makes every negative test definitive or establishes that testing is useless. Quoting one percentage without its denominator obscures the actual uncertainty.
| Question | Useful distinction |
|---|---|
| Was any reaction positive? | That is different from an allergen explaining today's rash. |
| Were most paired tests unchanged? | Agreement across all tests differs from retaining prior positives. |
| Was a reaction lost? | Timing, testing conditions and treatment need review. |
| Did avoidance help? | Clinical relevance involves exposure and response, not testing alone. |
Coordinate testing with the treating team
The AAD explains that patch testing investigates delayed skin reactions and requires appropriate preparation and follow-up readings. Give the testing clinic a complete medicine history and copies of previous results, including reaction strength and date when available. Do not stop dupilumab, topical treatment or another medicine independently to try to improve a test.
Bring actual labels for cosmetics, work exposures and prescribed products used near the affected area. Ask whether the planned allergen series fits those exposures and what a negative result would mean in your circumstances. If a reaction is judged relevant, request a practical avoidance plan rather than avoiding every ingredient with an unfamiliar name.
Testing is one part of reassessment
Our patch-versus-prick guide explains why these tests answer different questions. A new facial or neck eruption on dupilumab can also have several explanations. Contact testing may be useful, but it should not replace examination or automatically label every residual rash an allergy.
Keep other explanations in view
Patch testing for delayed contact allergy does not answer every allergy question. The distinction between oat sensitization and clinical food allergy is another example of why exposure history and the type of test matter. For head-and-neck disease, a small oral antifungal trial explored a different question; it does not establish that every residual facial eruption needs antifungal treatment.
Sources and reading notes
- Prospective multicenter patch-testing study
- 2021 retrospective patch-test reproducibility evaluation
- AAD: patch testing
Prepared by the Dr. Arsy Editorial Team. Sources checked November 8, 2026. Educational information; this article does not imply independent clinician review. PubMed indexing is not NIH endorsement. The cited researchers do not endorse #003. The product image is an AI-created editorial scene based on the actual jar, not a patient photograph or a study result.